FER1L4 and hepatocellular carcinoma: On the other hand, many studies indicated FER1L4 as a tumor suppressor in prostate (Huo et al., 2020[27]), esophageal (Ma et al., 2018[45]), lung (Gao et al., 2019[18]; Ouyang et al., 2021[52]), gastric cancers (Xu et al., 2020[73]; Xia et al., 2015[71]), glioma (Xia et al., 2019[70]), osteosarcoma (Ye et al., 2019[77]; Fei et al., 2018[14]; Ma et al., 2019[44]), endometrial carcinoma (Qiao and Li, 2016[53]) and hepatocellular carcinoma (Wang et al., 2019[67]; Sun et al., 2019[62]).